# A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

> **NCT04746040** · PHASE1 · UNKNOWN · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Bioequivalence
- Asthma

## Interventions

- **DRUG:** Test
- **DRUG:** Reference

## Key facts

- **NCT ID:** NCT04746040
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-18
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-05-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04746040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04746040, "A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04746040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*